No analysts currently cover Vir Biotechnology with a public price target. We add the price target automatically as soon as at least one analyst publishes a rating. Until then, use the technical analysis and the key figures below.
10 analysts cover Vir Biotechnology. There is broad agreement on a positive view — 100% recommend buying.
Vir Biotechnology is classified as a growth stock with quarterly earnings growth of 58.5% and strong long-term momentum of 0.0%.
The P/S ratio is 5.9 (high — the market pays a premium for the revenue). The P/B ratio is 0.8, below book value, which can point to a value opportunity.
Vir Biotechnology and an operating margin of 30.8%. The latest quarterly earnings grew 58.5% year over year — strong growth.
The Piotroski score is 5 out of 9 — average financial health. Altman Z2 is 2.14 (middle zone — moderate). The debt-to-equity ratio (D/E) is 21.6% — low debt, a solid balance sheet.
Short interest is 8.96% — elevated, some investors are betting on a decline.
In 2026, insiders at Vir Biotechnology have made 20 transactions, all of which were sales. On a net basis, insiders took $2,429,558 out of the stock. Active insiders include Sabatini Brent, Napolitano Janet, SATO VICKI L and others.
There has been no insider trading in the last 3 months.
Insiders have exclusively sold shares in the recent period. This can suggest management sees limited opportunity.
Across the last 20 transactions: 0 purchases and 20 sales. A net $2,429,558 out of the stock.
Latest sale: Sabatini Brent sold 379 shares at $9.45 each on 2026-06-01.
Who is selling: Sabatini Brent, Napolitano Janet, SATO VICKI L, De Backer Marianne, Eisner Mark and others.
The table shows the last 20 reported insider transactions in Vir Biotechnology. Green rows are purchases, red rows are sales. The data is based on official filings.
| Transaction date | Name | Type | Number of shares | Price per share ($) | Total amount ($) |
|---|---|---|---|---|---|
| 2026-06-01 | Sabatini Brent | Sell | 379 | 9 | 3,582 |
| 2026-06-01 | Napolitano Janet | Sell | 3,200 | 9 | 30,240 |
| 2026-05-01 | SATO VICKI L | Sell | 22,000 | 10 | 221,100 |
| 2026-04-06 | De Backer Marianne | Sell | 72,559 | 9 | 664,640 |
| 2026-04-01 | SATO VICKI L | Sell | 22,000 | 9 | 199,540 |
| 2026-03-23 | Sabatini Brent | Sell | 7,711 | 9 | 70,324 |
| 2026-03-02 | SATO VICKI L | Sell | 21,800 | 10 | 217,564 |
| 2026-02-25 | Eisner Mark | Sell | 1,889 | 10 | 18,550 |
| 2026-02-25 | de Verneuil Vanina | Sell | 13,700 | 10 | 134,534 |
| 2026-02-24 | SATO VICKI L | Sell | 42,377 | 10 | 434,788 |
The following insiders have sold shares: Sabatini Brent, Napolitano Janet, SATO VICKI L, De Backer Marianne, Eisner Mark and others. In total, $2,429,558 was sold across 20 transactions. Insider trades are legal transactions in which executives and board members buy or sell shares of their own company. These transactions are reported to the SEC and are publicly available.
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 27, 2026.
Vir Biotechnology, Inc is in a short-term downtrend. The price of $10.57 is 2.9% below the 20-day average ($10.89). Medium term, the picture is negative: the price is 1.5% below the 50-day average ($10.73). Long term, the stock is 12.6% above the 200-day average ($9.39), which confirms a long-term uptrend.
Golden Cross: The 50-day average (10.73) is above the 200-day average (9.39), which is a classic bullish signal for Vir Biotechnology, Inc.
Vir Biotechnology, Inc has an RSI of 47.8, right in the middle of the neutral zone. There is no clear buying or selling pressure.
Daily MACD: MACD is negative (-0.092), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is below the signal line (-0.011) by 0.081, which confirms growing negative momentum in the downtrend.
Weekly MACD: MACD5 is positive (0.605), which indicates a broader bullish long-term trend. MACD5 is below the signal line (0.609) by 0.004, which suggests the long-term momentum is fading – the positive trend could come under pressure.
Overall MACD assessment: The daily and weekly MACD give conflicting signals. The long-term trend is bullish, but the short-term trend is bearish. Short-term momentum is still falling – a deeper pullback is possible.
Trend: Positive. The price trades above SMA50 and SMA200.
MACD trend (zero line): Daily bearish (-0.092). Weekly bullish (0.605).
MACD momentum (signal): Daily falling. Weekly falling.
RSI: 47.8 – neutral.
Technical signal: Buy
The broader trend is positive and MACD supports the picture. Consider buying with a stop-loss below the nearest support level.
Compare Vir Biotechnology with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.
See all 116 stocks in the Healthcare sector